Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + olodaterol 24-hour lung function crossover trial in COPD
2011-004710-42Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: FEV1 AUC0-24h response. Started Jan 2012; status: completed.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-004710-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004710-42.